U.S. market Closed. Opens in 16 minutes

CADL | Candel Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/A125.00K125.00K125.00K125.00K
Cost of Revenue23.98M987.00K232.00KN/A6.61M
Gross Profit-23.98M-862.00K-107.00K125.00K-6.48M
Operating Expenses14.41M34.80M24.77M13.31M8.59M
Selling, General & Admin14.41M14.06M10.67M5.18M2.56M
Research & Development24.51M20.79M15.18M8.75M6.61M
Other Operating Expenses-24.51M-48.00K-1.08M-624.00K-571.00K
Operating Income-38.39M-34.72M-25.73M-13.81M-9.04M
Other Expenses / Income452.00K15.93M-10.40M-3.87M797.00K
Before Tax Income-37.94M-18.79M-36.12M-17.68M-8.24M
Income Tax ExpensesN/A-15.93M53.00K4.49M-226.00K
Net Income-37.94M-2.87M-36.18M-22.17M-8.01M
Interest Expenses514.00K490.00K53.00KN/AN/A
Basic Shares Outstanding28.94M28.82M28.69M29.15M29.15M
Diluted Shares Outstanding28.94M28.82M28.69M29.15M29.15M
EBITDA-37.43M-17.32M-25.49M-13.72M-8.20M
EBITDA Margin0.00%-13,853.60%-20,395.20%-10,975.20%-6,557.60%
EBIT-37.42M-18.30M-36.07M-17.68M-8.24M
EBIT Margin0.00%-14,643.20%-28,856.80%-14,144.00%-6,592.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙